For instance, for some of these things, standard of care would include other potential medications as well or, in that particular situation, lowering phosphorus in the diet and that sort of thing.
I should say that in some of these examples, if they're not able to get regulatory approval, they will move on to do studies that look at clinical end points. They have started a big study that will give us that data over the next three to four years. Investing in these drugs before that may not be a wise investment if we don't know that it actually improves the health of Canadians, which is what we're trying to promote.